-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The company held a signing ceremony with Zhengzhou University for a groundbreaking project on a novel first-in-class drug aimed at combating liver fibrosis.
Category:
Time：2018-11-08
On March 3, the company held a signing ceremony with Zhengzhou University for a novel Class 1.1 drug aimed at combating liver fibrosis. Attending the ceremony and delivering remarks were Liu Jiong Tian, President of Zhengzhou University; Professor Dai Guifu and his project team; Su Xuejun, General Manager of the company; and Yin Dianshu, Director of the Shisi Pharmaceutical Research Institute. In recent years, in order to accelerate its strategic transformation and upgrading, Shisi Pharmaceutical has made significant adjustments to its R&D structure and layout, focusing its innovative vision on areas such as the development of major national innovative drugs. To this end, the company has successively established high-end R&D innovation platforms—including postdoctoral research workstations, academician workstations, and Nobel Prize-winning scientist workstations—and has actively collaborated with research institutions and universities on forward-looking initiatives.
On March 3, the company held a signing ceremony with Zhengzhou University for a novel Class 1.1 drug aimed at combating liver fibrosis. Attending the ceremony and delivering remarks were Liu Jiongtian, President of Zhengzhou University; Professor Dai Guifu and his project team; Su Xuejun, General Manager of the company; and Yin Dianshu, Director of the Shi Si Pharmaceutical Research Institute.
In recent years, to accelerate its strategic transformation and upgrading, Shiyao Group has vigorously adjusted its R&D structure and layout, focusing its innovative vision on areas such as the development of nationally significant innovative drugs. The company has successively established high-end R&D innovation platforms—including postdoctoral research workstations, academician workstations, and Nobel Prize-winning researcher workstations—and has actively engaged in forward-looking and practical collaborations with research institutions and universities, continuously enhancing its R&D innovation capabilities.
It is understood that liver fibrosis affects a large number of patients worldwide. Liver fibrosis represents a common pathological stage shared by various chronic liver injuries; in severe cases, it can progress to cirrhosis, ultimately leading to liver failure and even liver cancer. Currently, there are no effective drugs available to reverse liver fibrosis. As the leader of the innovative science and technology team for “Anti-Infective and Anti-Tumor Drug Research and Development” in Henan Province and an expert in the major national science and technology project “Major New Drug Creation during the 13th Five-Year Plan,” Professor Dai Guifu from Zhengzhou University—leading the research and development team for Zhengzhou University’s “Innovative Drug ADN-9 for the Treatment of Liver Fibrosis”—has conducted systematic research on this project for over a decade. According to reports, the innovative drug ADN-9 is derived from the natural product andrographolide. Through systematic molecular optimization and targeted indication screening, a drug molecule with particularly remarkable efficacy in treating liver fibrosis has been identified. Administered orally, ADN-9 exhibits high efficacy, low toxicity, and multi-target synergistic effects, fully demonstrating the therapeutic advantages of natural medicines in addressing complex diseases.
At the signing ceremony, Mr. Su Xuejun, General Manager of the company, delivered an enthusiastic speech: “We have established a solid foundation of cooperation with Zhengzhou University. This signing ceremony will mark a new milestone in deepening our collaboration and achieving mutual success. We are confident that, through the joint efforts of both sides, we will surely turn the research on anti-hepatic fibrosis drugs into a model of university-enterprise cooperation. Our collaboration is bound to yield abundant rewards and will undoubtedly make new contributions to the development of both the university and the enterprise, as well as to the health of the people.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license